6-苯氧基-3-吡啶胺 | 25194-67-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 6-苯氧基-3-吡啶胺
• 英文名称: 6-phenoxy-pyridin-3-ylamine
• 英文别名: 6-phenoxypyridin-3-amine；2-phenoxy-5-amino-pyridine
• CAS: 25194-67-6
• 化学式: C₁₁H₁₀N₂O
• mdl: MFCD01692449
• 分子量: 186.213
• InChiKey: DETKIRMPBJPJRQ-UHFFFAOYSA-N

物化性质

• 熔点：
  71 °C
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R22,R36/37/38
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

SDS

Name:	6-Phenoxy-3-pyridinamine 95+% Material Safety Data Sheet
Synonym:
CAS:	25194-67-6

Section 1 - Chemical Product MSDS Name:6-Phenoxy-3-pyridinamine 95+% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
25194-67-6	6-Phenoxy-3-pyridinamine	95+%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Harmful if swallowed. Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 25194-67-6: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: brown
Odor: sweetish odor
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H10N2O
Molecular Weight: 186.21

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Acids, acid chlorides, strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 25194-67-6: US2141000 LD50/LC50:
CAS# 25194-67-6: Oral, mouse: LD50 = 500 mg/kg.
Carcinogenicity:
6-Phenoxy-3-pyridinamine - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 22 Harmful if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 25194-67-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 25194-67-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 25194-67-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-苯氧基-3-吡啶胺 在 盐酸 、 sodium nitrite 、 sodium azide 作用下， 以 水 、 乙酸乙酯 为溶剂， 反应 2.5h， 生成 5-azido-2-phenoxypyridine
  参考文献：
  名称：

  Hit-to-lead optimization of a latency-associated nuclear antigen inhibitor against Kaposi’s sarcoma-associated herpesvirus infections

  摘要：

  The Latency-associated nuclear antigen (LANA) plays a central role for the latent persistence of the Kaposi's Sarcoma Herpesvirus (KSHV) in the human host and helps to establish lifelong infections. Herein, we report our efforts towards hit-to-lead generation starting from a previously discovered LANADNA inhibitor. By tethering the viral genome to the host nucleosomes, LANA ensures the segregation and persistence of the viral DNA during mitosis. LANA is also required for the replication of the latent viral episome during the S phase of the cell cycle. We aim to inhibit the interaction between LANA and the viral genome to prevent the latent persistence of KSHV in the host organism. Medicinal chemistry-driven optimization studies and structure-activity-relationship investigation led to the discovery of an improved LANA inhibitor. The functional activity of our compounds was evaluated using a fluorescence polarization (FP)-based interaction inhibition assay and electrophoretic mobility shift assay (EMSA). Even though a crystal structure of the ligand protein complex was not available, we successfully conducted hit optimization toward a low micromolar protein-nucleic acid-interaction inhibitor. Additionally, we applied STD-NMR studies to corroborate target binding and to gain insights into the binding orientation of our most potent inhibitor, providing opportunities for further rational design of more efficient LANAtargeting anti KSHV agents in future studies. (C) 2020 The Author(s). Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2020.112525
• 作为产物：
  描述：

  2-溴-5-硝基吡啶 在 盐酸 、 tin 、 水 、 potassium carbonate 作用下， 以 二甲基亚砜 为溶剂， 反应 6.0h， 生成 6-苯氧基-3-吡啶胺
  参考文献：
  名称：

  取代的2-苯氧基吡啶衍生物和金X射线晶体结构，二氯Cycloauration [2 - [[5 - [（环戊基氨基）羰基] -2-吡啶基-κ Ñ ]氧基]苯基κ Ç ] - ，（SP - 4-3）-

  摘要：

  在CH 3 CN / H 2 O介质中对吡啶环5位上具有不同取代基的2-苯氧基吡啶进行直接环化，从而分离出环化化合物AuCl 2（L）（HL =取代的2-苯氧基吡啶配体）具有烷基，取代的烷基，苯基，卤素，酯基和酰胺基。化合物的制备包括在室温下通过吡啶配体与NaAuCl 4的配位反应形成中间体AuCl 3（HL），然后在高温下在CH 3 CN / H 2中形成Au-C键。哦，中等。庞大的亲脂性基团的存在降低了环化化合物的收率，并有利于反应物种分解成Au（0）。对于在吡啶环中具有强吸电子取代基（硝基或腈）的配体，未观察到配位反应。具有供电子二甲基氨基的配体在室温下被NaAuCl 4氧化。噻吩基或乙酰基的存在允许分离中间体AuCl 3（HL），但对随后的循环auauration有不利影响。甲基取代的2-苯氧基吡啶配体的直接环金原子化的结果表明，在吡啶环中最靠近Au-N（py）键的6位甲基的存在导

  DOI：

  10.1016/s0022-328x(03)00347-4

文献信息

• Parallel Solution-Phase Synthesis and General Biological Activity of a Uridine Antibiotic Analog Library
  作者：Omar Moukha-chafiq、Robert C. Reynolds

  DOI：10.1021/co4001452

  日期：2014.5.12

  coupling of the amino terminus of d-phenylalanine methyl ester to the free 5′-carboxylic acid moiety of 33 followed by sodium hydroxide treatment led to carboxylic acid analog 77. Hydrolysis of this material gave analog 78. The intermediate 77 served as the precursor for the preparation of novel dipeptidyl uridine analogs 79–99 through peptide coupling reactions to diverse amine reactants. None of the described

  在 NIH 路线图计划的中试规模库 (PSL) 计划下，以溶液相方式从胺2和羧酸33和77合成了一个包含 94 种尿苷抗生素类似物的小型库。多样醛，磺酰氯，和羧酸反应物套缩合，2，酸介导的水解导致后，向目标化合物3 - 32以良好的收率和高的纯度。同样，用不同的胺和磺胺处理33得到34 – 75。d氨基末端的偶联-苯丙氨酸甲酯到33的游离 5'-羧酸部分，然后用氢氧化钠处理产生羧酸类似物77。该材料的水解得到类似物78。中间77担任该前体为二肽基新颖尿苷类似物的制备79 - 99通过肽偶联到不同的胺反应剂反应。所描述的化合物均未显示出显着的抗癌或抗疟活性。通过 NIH MLPCN 计划提供和报告的初级筛选中的酶和受体，许多样品表现出各种有希望的抑制性、激动剂、拮抗剂或激活剂特性。
• Parallel Solution Phase Synthesis and Preliminary Biological Activity of a 5′-Substituted Cytidine Analog Library
  作者：Omar Moukha-Chafiq、Robert C. Reynolds、Jacob C. Wilson、Timothy S. Snowden

  DOI：10.1021/acscombsci.9b00072

  日期：2019.9.9

  NIH Roadmap Initiative and the Pilot Scale Library (PSL) Program. Reaction core compounds contained -NH2 (2) and -COOH (44 and 93) groups that were coupled to a diversity of reactants in a parallel, solution phase format to produce the target library. The assorted reactants included -NH2, -CHO, -SO2Cl, and -COOH functional groups, and condensation with the intermediate core materials 2 and 44 followed

  通过美国国立卫生研究院路线图计划和中试规模库（PSL）计划的资助，合成了一个由109个成员组成的5'-取代胞苷类似物库。反应核心化合物包含-NH2（2）和-COOH（44和93）基团，这些基团以平行溶液相的形式与多种反应物偶联，生成目标库。所分类的反应物包括-NH 2，-CHO，-SO 2 Cl和-COOH官能团，并且与中间核材料2和44缩合，然后进行酸性水解，以良好的产率和高纯度产生了3-91。d-苯丙氨酸甲酯的氨基末端与44和NaOH处理的游离5'-COOH的连接产生了核心库-COOH前体93。化合物93是我们独特的二肽基胞苷类似物94-114文库的重要组成部分，它通过-COOH基团与众多商业胺的酰胺偶联，然后进行酸性脱保护作用。通过MLPCN程序对完整的最终文库进行的初步筛选显示，在不同的生物学过程中命中数不多。这些命中可以被认为是命中率领先的优化和开发研究的起点。
• [EN] THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES<br/>[FR] COMPOSÉS CONTENANT DES GROUPES THIAZOLYLE POUR LE TRAITEMENT DE MALADIES PROLIFÉRATIVES
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2016065138A1

  公开（公告）日：2016-04-28

  The present disclosure provides thiazolyl-containing compounds of Formula (I), (II), or (III). The compounds described herein may be able to inhibit protein kinases (e.g., Src family kinases (e.g., hemopoietic cell kinase (HCK)), Bruton' s tyrosine kinase (BTK)) and may be useful in treating and/or preventing proliferative diseases (e.g., myelodysplasia, leukemia, lymphoma (e.g., Waldenstrom's macroglobulinemia)) and in inducing apoptosis in a cell (e.g., malignant blood cell). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

  本公开提供了含有噻唑基的公式(I)、(II)或(III)的化合物。本文所述的化合物可能能够抑制蛋白激酶（例如，Src家族激酶（例如，造血细胞激酶（HCK）），布伦顿酪氨酸激酶（BTK））并且在治疗和/或预防增殖性疾病（例如，骨髓增生异常综合征、白血病、淋巴瘤（例如，瓦尔德斯特伦巨球蛋白血症））以及在细胞（例如，恶性血细胞）中诱导凋亡方面可能有用。本公开还提供了包括或使用本文所述化合物的药物组合物、试剂盒、方法和用途。
• [EN] INHIBITORS OF BRUTON'S TYROSINE KINASE<br/>[FR] INHIBITEURS DE LA TYROSINE KINASE DE BRUTON
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015086636A1

  公开（公告）日：2015-06-18

  This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are useful for the treatment of oncological, auto-immune, and inflammatory diseases caused by aberrant B-cell activation. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.

  该应用程序根据通用公式（I）披露化合物：其中所有变量的定义如本文所述，这些化合物抑制Btk。本文披露的化合物对调节Btk的活性并治疗与过度Btk活性相关的疾病有用。这些化合物对于治疗由异常B细胞活化引起的肿瘤学、自身免疫和炎症性疾病是有用的。还披露了含有公式I化合物和至少一种载体、稀释剂或赋形剂的组合物。
• [EN] INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE<br/>[FR] INHIBITEURS DE TYROSINE KINASE DE BRUTON ET LEURS PROCÉDÉS D'UTILISATION
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2018103058A1

  公开（公告）日：2018-06-14

  Compounds of formula (I') and methods of their use and preparation, as well as compositions comprising compounds of formula (I').

  公式（I'）的化合物及其使用和制备方法，以及包含公式（I'）化合物的组合物。